Secondary T-cell lymphoblastic lymphoma in a child after anticancer therapy for neuroblastoma: clinical case
https://doi.org/10.21682/2311-1267-2020-7-2-115-9
Abstract
Neuroblastoma (NB) is the most common extra-cranial solid tumor in infants with the most heterogeneous clinical course to compare with other malignant diseases. Due to intensive multimodal anticancer treatment there are an increased number of survivors and issues related to long-term effects are becoming increasingly important. One of them is the risk of secondary malignant neoplasms. This article represents a clinical case of T-cell lymphoblastic leukemia in a child aged 2 years and 5 months who received combined antitumor therapy for NB with an intermediate risk group under the age of one year. We observed literature data to investigate the incidence of second malignant neoplasms in patients with NB for the period from 1948 to 2018 and analyzed risk factors.
About the Authors
Yu. K. Toshina
Almazov National Medical Research Centre, Ministry of Health of Russia
Russian Federation
Russian Federation
Yu.K. Toshina, Pediatric Oncologist, Department of Chemotherapy for Hematologic Diseases and Bone Marrow Transplantation for Children
2 Akkuratova St., S.-Petersburg, 197341, Russia
Yu. V. Dinikina
Almazov National Medical Research Centre, Ministry of Health of Russia; Saint-Petersburg State Pediatric Medical University, Ministry of Health of Russia
Russian Federation
Russian Federation
Cand. of Sci. (Med.), Head of the Department of Chemotherapy for Hematologic Diseases and Bone Marrow Transplantation for Children; Associate Professor Department of Oncology, Pediatric Oncology and Radiotherapy
2 Akkuratova St., S.-Petersburg, 197341, Russia
2 Litovskaya St., S.-Petersburg, 194100, Russia
A. S. Egorov
Almazov National Medical Research Centre, Ministry of Health of Russia
Russian Federation
Russian Federation
Cand. of Sci. (Med.), Hematologist Department of Chemotherapy for Hematologic Diseases and Bone Marrow Transplantation for Children
2 Akkuratova St., S.-Petersburg, 197341, Russia
A. Yu. Smirnova
Almazov National Medical Research Centre, Ministry of Health of Russia
Russian Federation
Russian Federation
Pediatric Oncologist Department of Chemotherapy for Hematologic Diseases and Bone Marrow Transplantation for Children
2 Akkuratova St., S.-Petersburg, 197341, Russia
M. B. Belogurova
Almazov National Medical Research Centre, Ministry of Health of Russia; Saint-Petersburg State Pediatric Medical University, Ministry of Health of Russia
Russian Federation
Leading Scientific Collaborator of Research Institute of Oncology and Hematology; Dr. of Sci. (Med.), Professor, Head of the Department of Oncology, Pediatric Oncology and Radiotherapy
Russian Federation
Leading Scientific Collaborator of Research Institute of Oncology and Hematology; Dr. of Sci. (Med.), Professor, Head of the Department of Oncology, Pediatric Oncology and Radiotherapy
2 Akkuratova St., S.-Petersburg, 197341, Russia
2 Litovskaya St., S.-Petersburg, 194100, Russia
References
1. Federico S.M., Allewelt H.B., Spunt S.L., Hudson M.M., Wu J., Billups C.A., Jenkins J., Santana V.M., Furman W.L., McGregor L.M. Subsequent malignant neoplasms in pediatric patients initially diagnosed with neuroblastoma. J Pediatr Hematol Oncol 2015;37(1):e6–12. doi: 10.1097/mph.0000000000000148.
2. Laverdière C., Liu Q., Yasui Y., Nathan P.C., Gurney J.G., Stovall M., Diller L.R., Cheung N.K., Wolden S., Robison L.L., Sklar C.A. Longterm outcomes in survivors of neuroblastoma: a report from the Childhood Cancer Survivor Study. J Natl Cancer Inst 2009;101(16):1131–40. doi: 10.1093/jnci/djp230.
3. Applebaum M.A., Henderson T.O., Lee S.M., Pinto N., Volchenboum S.L., Cohn S.L. Second malignancies in patients with neuroblastoma: the effects of risk-based therapy. Pediatr Blood Cancer 2015;62(1):128–33. doi: 10.1002/pbc.25249.
4. Applebaum M.A., Vaksman Z., Lee S.M., Hungate E.A., Henderson T.O., Londone W.B., Pinto N., Volchenboum S.L., Park J.R., Naranjo A., Hero B., Pearson A.D., Stranger B.E., Cohn S.L., Diskin S.J. Neuroblastoma survivors are at increased risk for second malignancies: a report from the International Neuroblastoma Risk Group Project. Eur J Cancer 2017;72:177–85. doi: 10.1016/j.ejca.2016.11.022.
5. Rubino C., Adjadj E., Gurerin S., Guibout C., Shamsadin A., Dondon M.-G., Valteau-Couanet D., Hartmann O., Hawkins M., de Vathaire F. Long-term risk of second malignant neoplasm after neuroblastoma in childhood: role of treatment. Int J Cancer 2003;107:791–6. doi: 10.1002/ijc.11455.
6. Kushner B.H., Kramer K., Modak S., Qin L.X., Yataghena K., Jhanwar S.C., Cheung N.K. Reduced risk of secondary leukemia with fewer cycles of dose-intensive induction chemotherapy in patients with neuroblastoma. Pediatr Blood Cancer 2009;53:17–22. doi: 10.1002/pbc.21931.
7. Martin A., Schneiderman J., Helenowski I.B., Morgan E., Dilley K., Danner-Koptik K., Hatahet M., Shimada H., Cohn S.L., Kletzel M., Hijiya N. Secondary malignant neoplasms after high-dose chemotherapy and autologous stem cell rescue for high-risk neuroblastoma. Pediatr Blood Cancer 2014;61(8):1350–6. doi: 10.1002/pbc.25033.
8. Garaventa A., Gambini C., Villavecchia G., Cataldo A., Bertolazzi L., Pizzitola M.R., de Bernardi B., Haupt R. Second malignancies in children with neuroblastoma after combined treatment with 131I-metaiodobenzylguanidine. Cancer 2002;97(5):1332–8. doi: 10.1002/cncr.11167.
9. Huibregtse K.E., Kieuhoa T.V., Du Bois S.G., Fetzko S., Neuhaus J., Batra V., Maris J.M., Weiss B., Marachelian A., Yanik G.A., Matthay K.K. Incidence and risk factors for secondary malignancy in patients with neuroblastoma after treatment with 131I-metaiodobenzylguanidine. Eur J Cancer 2016;66:144–52. doi: 10.1016/j.ejca.2016.07.017.
10. Moroz М., Machin D., Faldum A., Hero B., Iehara T., Mosseri V., Ladenstein R., de Bernardi B., Rubie H., Berthold F., Matthay K.K., Monclair T., Ambros P.F., Pearso A.D.J., Cohn S.L., London W.B. Changes over three decades in outcome and the prognostic infl uence of age-at-diagnosis in young patients with neuroblastoma: a report from the International Neuroblastoma Risk Group Project. Eur J Cancer 2011;47(4):561–71. doi:10.1016/j.ejca.2010.10.022.
11. Sandoval С., Pui C.H., Bowman L.C., Heaton D., Raimondi S.C., Behm F.G., Head D.R. Secondary acute myeloid leukemia in children previously treated with alkylating agents, intercalating topoisomerase II inhibitors, and irradiation. J Clin Oncol1993;11(6):1039–45. doi: 10.1200/JCO.1993.11.6.1039.
12. Kushner B.H., Cheung N.K., Kramer K., Heller G., Jhanwar S.C. Neuroblastoma and treatment-related myelodysplasia/leukemia: the Memorial Sloan-Kettering experience and a literature review. J Clin Oncol 2016;16(12):3880–9. doi: 10.1200/jco.1998.16.12.3880.
13. Hijiya N., Ness K.K., Ribeiro R.C., Hudson M.M. Acute leukemia as a secondary malignancy in children and adolescents: current fi ndings and issues. Cancer 2016;115(1):23–35. doi: 10.1002/cncr.23988.
14. Barr E., Applebaum M. Genetic predisposition to neuroblastoma. Children 2018;5(9):119. doi:10.3390/children5090119.
Review
For citations:
Toshina Yu.K., Dinikina Yu.V., Egorov A.S., Smirnova A.Yu., Belogurova M.B. Secondary T-cell lymphoblastic lymphoma in a child after anticancer therapy for neuroblastoma: clinical case. Russian Journal of Pediatric Hematology and Oncology. 2020;7(2):115-119. (In Russ.) https://doi.org/10.21682/2311-1267-2020-7-2-115-9
Views:
756
Email this article 